Visual Function and Freedom from Disease Activity in a Phase 3 Trial for Relapsing Multiple Sclerosis

Update Item Information
Identifier 20130212_nanos_posters_005
Title Visual Function and Freedom from Disease Activity in a Phase 3 Trial for Relapsing Multiple Sclerosis
Creator Laura J. Balcer; Steven L. Galetta; Annie Zhang; Ryan Arnold
Affiliation (LJB) (SLG) NYU School of Medicine, New York, NY; (AZ) (RA) Biogen-Idec, Cambridge, MA
Subject Visual Function; Multiple Sclerosis; Low-Contrast Letter Acuity; Natalizumab
Description In the phase 3 trial of natalizumab for relapsing MS (AFFIRM), low-contrast letter acuity (LCA) showed decreased probability of sustained visual loss in patients receiving active treatment. Freedom from clinical and radiological disease activity was also seen in 37% of treated patients over 2 years in AFFIRM. Given the importance of vision to overall functioning and quality of life in MS, we determined how freedom from disease activity might be associated with visual loss.
Date 2013-02-12
Language eng
Format application/pdf
Type Text
Source 2013 North American Neuro-Ophthalmology Society Annual Meeting
Relation is Part of NANOS 2013: Poster Presentations
Collection Neuro-Ophthalmology Virtual Education Library: NANOS Annual Meeting Collection: https://novel.utah.edu/collection/nanos-annual-meeting-collection/
Publisher North American Neuro-Ophthalmology Society
Holding Institution Spencer S. Eccles Health Sciences Library, University of Utah
Rights Management Copyright 2013. For further information regarding the rights to this collection, please visit: https://NOVEL.utah.edu/about/copyright
ARK ark:/87278/s6dn7brf
Setname ehsl_novel_nam
ID 183354
Reference URL https://collections.lib.utah.edu/ark:/87278/s6dn7brf
Back to Search Results